Beyond Anemia: The clinical impact of the physiologic effects of erythropoietin

Seminars in Dialysis

Volumn 21, Issue 5, 2008, Pages 447-454

  Diskin, Charles J ^a   Stokes, Thomas J ^a   Dansby, Linda M ^a   Radcliff, Lautrec ^a   Carter, Thomas B ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; HYPERTENSION; LUNG GAS EXCHANGE; METABOLISM; NEOPLASM; OXYGEN CONSUMPTION; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; THROMBOSIS;

DIABETIC RETINOPATHY; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; NEOPLASMS; OXYGEN CONSUMPTION; RENAL DIALYSIS; RESPIRATORY TRANSPORT; THROMBOSIS;

EID: 54749092516     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2008.00443.x     Document Type: Article

References (126)

1. Jourdanet D. De l'anemie des altitudes et de l'anemie en general dans ses rapports avec la pression de l'atmosphere. Paris : Baiilere, 1863
2. Bert P : Sur la richesse en hemoglobine due sang des anumaux vivant sur les hautes lieux. Comp Rend Acad d sc 94 : 805 806, 1882
3. Viault F : Sur l'augmentation considerable du nombre des globules rouges dans sang chez les habitants des haut plateaux de' l Amerique du Sud. Comp. Rend Acad d sc 111 : 917 918, 1890
4. Herrara AL, Lope DV : Globules rouges et densite du sang, Chapitre V, Deuxieme partie, nombre (c) in La Vie sur les haut plateaux. Mexico City, Mexico : Smithsonian Institute, 1899
5. Bornstein A : Ueber den einfluss der konprimeirten Luft auf die Blutbildung. Pfuegers Arch f.d ges Physiol 138 : 609 610, 1911
6. Bonsdorff E, Jalavisto E : A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand XVI : 152, 1948
7. Goldwasser E, Kung CK : Progress in the purification of erythropoietin. Ann N Y Acad Sci 149 : 49 53, 1968
8. Miyake T, Kung CK, Goldwasser E : Purification of human erythropoietin. J Biol Chem 252 : 5558 5564, 1977
9. Garcia JF, Sherwood J, Goldwasser E : Radioimmunoassay of erythropoietin. Blood Cells 5 : 405 419, 1979
10. Kennedy WL, Alpen EL, Garcia JF : Erythroid colony production in vitro as a function of exposure time to erythropoietin. Blood Cells 4 : 143 154, 1978
11. Nathan DG, Sytkowski A : Editorial retrospective. Erythropoietin and the regulation of erythropoiesis. N Engl J Med 308 : 520 522, 1983
12. Faura J, Ramos J, Reynafarje C, English E, Finne P, Finch CA : Effect of altitude on erythropoiesis. Blood 33 : 668 676, 1969
13. Stockman JA 3rd, Garcia JF, Oski FA : The anemia of prematurity. Factors governing the erythropoietin response. N Engl J Med 296 : 647 650, 1977
14. Cohen RA, Miller ME, Garcia JF, Moccia G, Cronkite EP : Regulatory mechanism of erythropoietin production: effects of hypoxemia and hypercarbia. Exp Hematol 9 : 513 521, 1981
15. Pavlovic-Kentera V, Milenkovic P, Ruvidic R, Jovanovic V, Biljanovic-Paunovic L : Erythropoietin in aplastic anemia. Blut 39 : 345 350, 1979
16. Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP : Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 99 : 624 635, 1982
17. Miller ME, Cronkite EP, Garcia JF : Plasma levels of immunoreactive erythropoietin after acute blood loss in man. Br J Haematol 52 : 545 549, 1982
18. Varet B, Casadevall N, Lacombe C, Nayeaux P : Erythropoietin: physiology and clinical experience. Semin Hematol 27 (3 Suppl. 3 25 31, 1990
19. Diskin CJ, Jones KLO : Erythropoietin Levels in ESRD by Enzyme Immunoassay. P62, 1984 [ASN Abstract P. 62]
20. Diskin CJ, Jones KLO : Erythropoietin levels in ESRD by enzyme immunoassay. Kidney Int 27 : 160A, 1985 [Abstract].
21. Naets JP, Garcia JF, Tousaaint C, Buset M, Waks D : Radioimmunoassay of erythropoietin in chronic uraemia or anephric patients. Scand J Haematol 37 : 390 394, 1986
22. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM : Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 54 : 877 884, 1979
23. Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W : Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int 31 : 1205 1209, 1987
24. Ratcliffe PJ : Biology of erythropoietin. Kidney Int 44 : 887 904, 1993
25. Eckardt KU, Mollmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U : Erythropoietin in polycystic kidneys. J Clin Invest 84 : 1160 1166, 1989
26. Goldsmith HJ, Ahmad R, Raichura N, Lal SM, McConnell CA, Gould DA, Gyde OH, Green J : Association between rising haemoglobin concentration and renal cyst formation in patients on long term regular haemodialysis treatment. Proc Eur Dial Transplant Assoc 19 : 313 318, 1983
27. Bezerra HM, Maia GP, Bezerra Neto FA, Serra M, de Almeida JB : Severity of acquired cystic kidney disease determines improvement in chronic kidney failure anemia. Rev Assoc Med Bras 43 : 4 8, 1997
28. Gunga HC, Kirsch KA, Roecker L, Kohlberg E, Tiedemann J, Steinach M, Schobersberger W : Erythropoietin regulations in humans under different environmental and experimental conditions. Respir Physiol Neurobiol 158 : 287 297, 2007
29. Dornfest BS, Naughton BA, Johnson R, Gordon AS : Hepatic production of erythropoietin in a phenylhydrazine-induced compensated hemolytic state in the rat. J Lab Clin Med 102 : 274 285, 1983
30. Eschbach JW, Mladenovic J, Garcia JF, Wahl PW, Adamson JW : The anemia of chronic renal failure in sheep. Response to erythropoietin-rich plasma in vivo. J Clin Invest 74 : 434 441, 1984
31. Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ : Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 263 (3 Pt 2 F474 F481, 1992
32. Fried W, Barone-Varelas J, Barone T, Anagnostou A : Effect of angiotensin infusion on extrarenal erythropoietin production. J Lab Clin Med 99 : 520 525, 1982
33. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, et al. : Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82 : 7580 7584, 1985
34. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM : Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2 : 1175 1178, 1986
35. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A CREATE Investigators : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071 2084, 2006
36. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085 2098, 2006
37. FDA Alert. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Rockville, MD : Food and Drug Administration, March 9, 2007. Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm, accessed May 25, 2007
38. Kapitsinou PP, Haase VH : The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 15 : 650 659, 2008
39. Diskin CJ : Hemoglobin targets versus oxygen delivery: is it time for a new paradigm? Blood Purif 25 : 280, 2007
40. Diskin CJ : Hitting the target but missing the goal? Hemoglobin targets versus oxygen delivery Am J Kidney Dis 50 : 344, 2007
41. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB : Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients? Nephrology (Carlton) 11 : 394 399, 2006
42. Wright JR, Ung YC, Julian JA, et al. : Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer and disease-related anemia. J Clin Oncol 25 : 1027 1032, 2007
43. Henke M, Laszig R, Rübe C, et al. : Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 : 1255 1260, 2003
44. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. : Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 : 5960 5972, 2005
45. Bohlius J, Wilson J, Seidenfeld J, et al. : Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3 : CD003407, 2006
46. Fechner G, Müller G, Schmidt D, Garbe S, Hauser S, Vaupel P, Müller SC : Evaluation of hypoxia-mediated growth factors in a novel bladder cancer animal model. Anticancer Res 27 : 4225 4231, 2007
47. Berlyne GM, Diskin C, Gonick H, Dobbie J, Prasad A : Trace elements in dialysis patients. ASAIO Trans 32 : 662 670, 1986
48. Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumenti JF Jr : Cancer in patients receiving long-term dialysis treatment. Am J Epidemiol 126 : 370 376, 1987
49. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney APS, Briggs D, McCredie M, Boyle P : Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 354 : 93 99, 1999
50. Heidland A, Bahner U, Vamvakas S : Incidence and spectrum of dialysis-associated cancer in three continents. Am J Kidney Dis 35 : 347 351, 2000 discussion : 352 353
51. D'Andrea AD, Lodish HF, Wong GG : Expression cloning of the murine erythropoietin receptor. Cell 57 : 277 285, 1989
52. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF : Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A 98 : 4379 4384, 2001
53. D'Andrea AD, Fasman GD, Lodish HF : Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family. Cell 58 : 1023 1024, 1989
54. Bazan JF : Shared architecture of hormone binding domains in type I and II interferon receptors. Cell 61 : 753 754, 1990
55. Bazan JF : Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A 87 : 6934 6938, 1990
56. D'Andrea AD, Zon LI : Erythropoietin receptor. Subunit structure and activation. J Clin Invest 86 : 681 687, 1990
57. Yarden Y, Ullrich A : Growth factor receptor tyrosine kinases. Annu Rev Biochem 57 : 443 478, 1988
58. Kahn P, Frykberg L, Brady C, Stanley I, Beug H, Vennstrom B, Graf T : v-erbA cooperates with sarcoma oncogenes in leukemic cell transformation. Cell 45 : 349 356, 1986
59. Hoatlin ME, Kozak SL, Lilly F, Chakraborti A, Kozak CA, Kabat D : Activation of erythropoietin receptors by Friend viral gp55 and by erythropoietin and down-modulation by the murine Fv-2r resistance gene. Proc Natl Acad Sci U S A 87 : 9985 9989, 1990
60. Chretien S, Moreau-Gachelin F, Apiou F, Courtois G, Mayeux P, Dutrillaux B, Cartron JP, Gisselbrecht S, Lacombe C : Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells. Blood 83 : 1813 1821, 1994
61. Yoshimura A, Longmore G, Lodish HF : Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature 348 : 647 649, 1990
62. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ : Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66 : 135 145, 2006
63. Westenfelder C, Baranowski RL : Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58 : 647 657, 2000
64. Solar P, Feldman L, Jeong JY, Busingye JR, Sytkowski AJ : Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer 122 : 281 288, 2008
65. Henke M, Mattern D, Pepe M, et al. : Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24 : 4708 4713, 2006 [Erratum, J Clin Oncol 25:1457, 2007
66. Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M, Girard P, Validire P, Breau JL, Bernaudin JF, Soria JC : Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res 13 : 4825 4831, 2007
67. Carvalho G, Lefaucheur C, Cherbonnier C, Métivier D, Chapel A, Pallardy M, Bourgeade MF, Charpentier B, Hirsch F, Kroemer G : Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 24 : 737 745, 2005
68. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A : Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101 : 14907 14912, 2004 [Epub September 29, 2004]
69. Sytkowski AJ : Does erythropoietin have a dark side? Epo signaling and cancer cells Sci STKE 2007 : pe38, 2007
70. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M : Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 39 : 26 29, 1985
71. Kuehn EW, Walz G, Benzing T : von Hippel-Lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development. Cancer Res 67 : 4537 4540, 2007
72. Neumann HP, Schollmeyer P, Eggert HR, Jelkmann W, Wiestler OD : Serum erythropoietin levels in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 54 : 746 747, 1991
73. Errasti P, Manrique J, Lavilla J, Rossich E, Hernandez A, Pujante D, Ndarabu A, Garcia N, Purroy A : Autosomal-dominant polycystic kidney disease: high prevalence of graft loss for death-related malignancies and cardiovascular risk factors. Transplant Proc 35 : 1717 1719, 2003
74. Hughson MD, Buchwald D, Fox M : Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. Arch Pathol Lab Med 110 : 592 601, 1986
75. Diskin CJ, Stokes TJ, Dansby LM, Carter TB, Radcliff L, Monteil D : Diagnosis of tuberous sclerosis in a patient who presented with polycystic kidney disease. Nephrol Dial Transplant 15 : 547 548, 2000
76. Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA : Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int 70 : 1777 1782, 2006
77. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, DeClue JE : The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19 : 6306 6316, 2000
78. van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P : Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7 : 1053 1057, 1998
79. Gao X, Pan D : TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15 : 1383 1392, 2001
80. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr : TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 : 147 158, 2003
81. Rotter W, Roettger P : Comparative pathologic-anatomic study of cases of global renal insufficiency with and without preceding dialysis. Clin Nephrol 1 : 257 265, 1973
82. Guntupalli K, Soffer O, Baciewicz P : Pulmonary embolism in end stage renal disease. Intensive Care Med 16 : 405 407, 1990
83. Casserly LF, Reddy SM, Dember LM : Venous thromboembolism in end-stage renal disease. Am J Kidney Dis 36 : 405 411, 2000
84. Iannuzzelli A, Kasama R : Hypercoagulability in dialysis patients: fact or fiction? Am J Kidney Dis 37 : A20, 2001 [Abstract 38]
85. Tveit DP, Hypolite IO, Hshieh P, et al. : Chronic dialysis patients have a high risk for pulmonary embolism. Am J Kidney Dis 39 : 1011 1017, 2002
86. Corwin HL, Gettinger A, Fabian T, et al. : Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357 : 965 976, 2007
87. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU : Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26 : 592 598, 2008
88. Shinaberger JH, Miller JH, Gardner PW : Erythropoietin alert: risks of high hematocrit hemodialysis. ASAIO Trans 34 : 179 184, 1988
89. Diaz-Ricart M, Etebanell E, Cases A, Lopez-Pedret J, Castillo R, Ordinas A, Escolar G : Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 82 : 1312 1317, 1999
90. Macdougall IC, Davies ME, Hallett I, Cochlin DL, Hutton RD, Coles GA, Williams JD : Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 6 : 862 867, 1991
91. Taylor JE, Henderson IS, Stewart WK, Belch JJ : Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 338 : 1361 1362, 1991
92. Jaar B, Denis A, Viron B, Verdy E, Chamma F, Siohan P, Mignon F : Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation. Am J Nephrol 17 : 399 405, 1997
93. Viron B, Jaar B, Verdy E, Mignon F : Erythropoietin-induced protein S deficiency and vena cava thrombosis. Nephrol Dial Transplant 7 : 979, 1992
94. Hollan S, Johansen KS : Adequate iron stores and the 'Nil nocere' Principle. Haematologia (Budap) 25 : 69 84, 1993
95. Grandaliano G, Teutonico A, Allegretti A, Losappio R, Mancini A, Gesualdo L, Schena FP, Pertosa G : The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney Int 64 : 715 719, 2003
96. Diskin CJ, Stokes TJ, Pennell A : Pharmacologic intervention to prevent vascular access thrombosis. Nephron 64 : 1 26, 1993
97. Diskin CJ, Stokes TJ, Thomas SG, Ravis W, Lock S, Thomas J, Panus LW, Dansby L, Carter T : An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron 78 : 365 368, 1998
98. Diskin CJ : Notes on angiotensin inhibition and vascular access survival: time for randomized controlled trials. Nephrol Dial Transplant 21 : 823, 2006 [Epub ahead of print]
99. Saran R, Dykstra DM, Wolfe RA, et al. : Association between vascular access failure and the use of specific drugs: the dialysis outcomes and practice patterns study. Am J Kidney Dis 40 : 1255 1263, 2002
100. Sajgure A, Choudhury A, Ahmed Z, Choudhury D : Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency. Nephrol Dial Transplant 22 : 1390 1398, 2007 [Epub January 31 2007]
101. Navarro JF, Macia ML, Mora-Fernandez C, Gallego E, Chahin J, Mendez ML, del Castillo N, Rivero A, Garcia J : Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients. Adv Perit Dial 13 : 257 259, 1997
102. Du J, Peng T, Scheidegger KJ, Delafontaine P : Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol 19 : 2119 2126, 1999
103. Reddy MK, Vasir JK, Hegde GV, Joshi SS, Labhasetwar V : Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. J Cardiovasc Pharmacol Ther 12 : 237 247, 2007
104. Mohini R : Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. Semin Nephrol 9 (1 Suppl. 1 16 21, 1989
105. Hilden M, Leth A, Hilden T : High haemoglobin values during medical treatment of hypertension. Br Med J 3 : 163 165, 1968
106. Williams B, Edmunds ME, Thompson JP, Burton PR, Feehally J, Walls J : Does increasing haemoglobin concentration and haematocrit have a pressor effect in dialysis patients? Nephrol Dial Transplant 4 : 787 791, 1989
107. Volzhskaia AM, Volodina IL : Mechanism of development of erythrocytosis in spontaneous arterial hypertension in rats. Kardiologiia 25 : 75 77, 1985
108. Teruel JL, Pascual J, Jiménez M, Liaño F, Rivera M, Martínez J, Moya JL, Ortuño J : Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Nephron 58 : 135 137, 1991
109. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M : Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43 : 1010 1014, 1993
110. Kuriyama S, Tomonari H, Tokudome G, Kaguchi Y, Hayashi H, Kobayash H, Horiguchi M, Ishikawa M, Hara Y, Hosoya T : Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: a preliminary report. Hypertens Res 24 : 501 505, 2001
111. Wada Y, Matsuoka H, Tamai O, Kohno K, Okuda S, Imaizumi T : Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am J Hypertens 12 : 980 987, 1999
112. Morikawa K, Kuroda M, Hasegawa T : Is the intracellular calcium-mediated pathway involved in erythropoietin-induced hypertension? Nephron 65 : 503 504, 1993
113. Azzadin A, Bialkowska A, Buczko W, Malyszko J, Kalinowski M, Mysliwiec M : Serotonergic mechanism of erythropoietin-induced hypertension. Nephrol Dial Transplant 7 : 882 883, 1992
114. Maschio G : Erythropoietin and systemic hypertension. Nephrol Dial Transplant 10 (Suppl. 2 74 79, 1995
115. Lee MS, Lee JS, Lee JY : Prevention of erythropoietin-associated hypertension. Hypertension 50 : 439 445, 2007
116. Diskin CJ, Stokes TJ, Dansby L, Radcliff L, Carter T : A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure? Am J Med Sci 334 : 260 264, 2007
117. Thomas MC : The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. Semin Nephrol 26 : 275 282, 2006
118. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110 : 1677 1682, 2003
119. Watanabe D : Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. Nippon Ganka Gakkai Zasshi 111 : 892 898, 2007
120. Kase S, Saito W, Ohgami K, Yoshida K, Furudate N, Saito A, Yokoi M, Kase M, Ohno S : Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br J Ophthalmol 91 : 1376 1378, 2007
121. Takagi H, Watanabe D, Suzuma K, Kurimoto M, Suzuma I, Ohashi H, Ojima T, Murakami T : Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract 77 (Suppl. 1 S62 S64, 2007
122. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H : Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353 : 782 792, 2005
123. Jonas JB, Neumaier M : Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy. Clin Exp Ophthalmol 35 : 186 187, 2007
124. Chan CC, Collins AB, Chew EY : Molecular pathology of eyes with von Hippel-Lindau (VHL) disease: a review. Retina 27 : 1 7, 2007
125. Chen J, Connor KM, Aderman CM, Smith LE : Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 118 : 526 533, 2008
126. Friedman EA, Brown CD, Berman DH : Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis 26 : 202 208, 1995